Breaking News, Collaborations & Alliances

AbbVie, REGENXBIO Enter Eye Care Collaboration

Strategic partnership combines eye care and gene therapy expertise.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and REGENXBIO Inc. entered a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials using in-office suprachoroidal delivery.   REGENXBIO will ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters